The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.
The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...
A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
NIH-funded UT team and colleagues from Metagenomi Thereapeutics discovered highly efficient enzyme could enable targeted gene editing within the human body.
The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...
The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...
The US Food and Drug Administration (FDA) today issued a draft guidance for sponsors seeking approval of human gene therapy ...
The genome has thousands of genes that code for proteins, which help carry out many of the cell's important functions. But ...
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually.
Zacks Investment Research on MSN
Three best genomics stocks for your portfolio in 2026
An updated edition of the Feb. 20, 2026, article. Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results